Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphomas: A systematic review and proportionality meta-analysis.
e19045 Background: B-cell non-Hodgkin lymphomas (NHL) are a diverse group of malignancies with varying prognoses, and managing relapsed or refractory (R/R...
First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).
4591 Background: Standard of care for MIBC is RC with neoadjuvant chemotherapy (NAC), but ~50% of pts are ineligible for NAC and 5y survival for RC alone...
Association between body mass index and overall survival in veterans receiving immune checkpoint inhibitors.
11149 Background: While obesity is a well-established risk factor for cancer development, patients with obesity paradoxically demonstrate better survival...
Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer.
8078 Background: Since 2021, several immuno-oncology (IO) agents were approved for use in patients with resectable non-small cell lung cancer. In the phas...
Corticosteroid (CS) use and risk of adverse events (AEs) in patients (pts) treated for metastatic hormone-sensitive prostate cancer (mHSPC).
e17097 Background: Treatment (Tx) of mHSPC involves intensifying androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abir...
ANA trial: Development of a diagnostic test and dynamic evaluation of ctDNA to optimize follow-up and tailor treatment in patients with HPV-related cervical and anal tumors.
TPS5621 Background: Cervical and anal cancers treated with definitive radiotherapy (RT), with or without chemotherapy, frequently exhibit persistent disea...
Palliative care and hospice utilization in patients with refractory or relapsed diffuse large B-cell lymphoma in the era of novel therapies.
e24051 Background: Around 40% of patients with diffuse large-B cell lymphoma (DLBCL) experience relapsed/refractory (r/r) disease and have very poor progn...
ELEPHAS-01, ELEPHAS-02 and ELEPHAS-04: Multi-institutional observational prospective clinical trials to assess the accuracy of an ex vivo live tumor fragment platform for predicting immunotherapy response.
TPS2689 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, existing FDA approved companion diagnostic biomarke...
Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16+ oropharyngeal squamous cell carcinoma.
e18086 Background: Relapse is the primary cause of treatment failure after curative-intent treatment (chemoradiotherapy or surgery and adjuvant therapy) f...
Enhancing prognostic accuracy in lung cancer brain metastases through histopathologic feature integration and AI-based image analysis.
e13608 Background: The management of brain metastases from lung cancer has emerged as a critical aspect for enhancing both longevity and quality of life a...
Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
5563 Background: ctDNA is a promising biomarker for predicting disease progression, survival, and surgical outcomes in patients with solid tumors. In a ph...
Clinical outcomes for anemic patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
e23102 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing g...
Outcomes for patients with congenital hepatoblastoma: Have they changed since 2013?
e22019 Background: Congenital hepatoblastoma (cHB), hepatoblastoma diagnosed in the first month of life, is rare. Some previously reported data in 2013 we...
Early tumor response on 1-month CT as a predictor of 2-year local control following SBRT in pulmonary oligometastases: A multicenter retrospective study.
e20047 Background: Stereotactic body radiation therapy (SBRT) is a standard treatment for pulmonary oligometastases due to its high efficacy and low toxic...
Mesonephric-like adenocarcinoma: A single-institution experience.
e17657 Background: This study examines Mesonephric-like adenocarcinoma (MLA), a rare gynecologic malignancy, by comparing clinical characteristics, treatm...
Magnetic resonance imaging (MRI) radiomics as predictor of clinical outcomes to neoadjuvant immunotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy.
1567 Background: Muscle-invasive bladder carcinoma (MIBC) is a deadly disease, for which we pioneered the use of neoadjuvant immune-checkpoint inhibitors...
Real-world data on efficacy and safety of trifluridine-tipiracil and bevacizumabin refractory metastatic colorectal cancer.
e15583 Background: Metastatic colorectal cancer (mCRC) has undergone significant improvements in its treatment, with new agents that have increased overal...
Comparative analysis of stereotactic body radiotherapy (SBRT) vs. SBRT with bridge therapies for hepatocellular carcinoma patients awaiting liver transplantation: A multi-center study (2010-2020).
4143 Background: Locoregional therapies, including SBRT, are essential in managing hepatocellular carcinoma (HCC) patients awaiting liver transplantation....
Clinical profiles, patient expectations and outcomes from an integrative oncology clinic in India: A novel integrated model of care in oncology.
1631 Background: Integrative approaches are used in Oncology care, often as an auxiliary measure to the Standard of Care (SoC). There is paucity of data r...
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC).
1011 Background: ctDNA testing has emerged as a prognostic and predictive biomarker in the management of mBC. However, the relationship between ctDNA tren...
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC).
1040 Background: In aBC, trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in HER2-positive, HER2-low, and HER2-ultralow disease subtypes. However,...
ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
TPS619 Background: Adjuvant ET is the standard of care (SOC) for treating ER+/HER2- eBC. Despite advances to optimize adju...
Digital twins as simulations of individual cancer pathophysiology through extensive tumor profiling: A guide to successful disease management.
e23303 Background: Advances in tumor-specific therapies guided by molecular genetic profiling are increasingly being integrated into clinical oncology. Th...
A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors.
3107 Background: Protein arginine transferase 5 (PRMT5) overexpression plays an important role in pathogenesis of several cancers. LNP7457 is an investiga...
Efficacy of low-dose nivolumab combined with chemotherapy as neoadjuvant treatment for lung cancer.
TPS8121 Background: Immune checkpoint inhibitors have revolutionized cancer treatment, providing durable responses in a substantial subset of patients. Ho...